<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720807</url>
  </required_header>
  <id_info>
    <org_study_id>XH-21-001</org_study_id>
    <nct_id>NCT04720807</nct_id>
  </id_info>
  <brief_title>Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer</brief_title>
  <official_title>Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer: a Prospective, Single-arm, Open Label, Exploratory Phase 2 Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which&#xD;
      aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in&#xD;
      platinum-resistant recurrent ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which&#xD;
      aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in&#xD;
      platinum-resistant recurrent ovarian cancer.The patient has undergone surgery and received ≥2&#xD;
      lines of platinum-containing chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>3 years</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years and 5 years</time_frame>
    <description>progression-free survival time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years and 5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>3 years and 5 years</time_frame>
    <description>Adverse event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Platinum-resistant Recurrent Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole combined with anlotinib hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole combined with anlotinib hydrochloride</intervention_name>
    <description>Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.</description>
    <arm_group_label>Letrozole combined with anlotinib hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older;&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;&#xD;
&#xD;
          3. Histologically diagnosed epithelial ovarian cancer (high-grade serous, clear cell,&#xD;
             endometrioid ovarian cancer), fallopian tube cancer or primary peritoneal cancer;&#xD;
&#xD;
          4. The patient has undergone surgery and received ≥2 lines of platinum-containing&#xD;
             chemotherapy. During the treatment period of the platinum-containing regimen (from the&#xD;
             beginning of the treatment to 1 month after the last chemotherapy), the curative&#xD;
             effect is non-PD, and the disease relapse/progress within 6 months after the&#xD;
             treatment；&#xD;
&#xD;
          5. The patient has measurable lesions with imaging evidence;&#xD;
&#xD;
          6. The expected survival period ≥ 3 months;&#xD;
&#xD;
          7. Estrogen receptor (ER) is positive in immunohistochemistry of the first or the last&#xD;
             surgical specimens;&#xD;
&#xD;
          8. Adequate organ function at screening:&#xD;
&#xD;
        1) Adequate bone marrow function at screening: Hemoglobin ≥90 g/L (no blood transfusion&#xD;
        within 14 days); Neutrophil ≥1.5×109/L; Platelets ≥80×109/L; 2) Biochemical test: Total&#xD;
        bilirubin≤1.5×ULN (upper limit of normal); Alanine aminotransferase (ALT) or aspartate&#xD;
        aminotransferase (AST) ≤ 2.5×ULN; if there is liver metastasis, ALT or AST ≤ 5×ULN; Serum&#xD;
        creatinine ≤ 1.5×ULN or endogenous creatinine clearance ≥ 50ml/min (Cockcroft-Gault&#xD;
        formula); 9. The patient has not been treated with other tyrosine kinase inhibitor (TKI)&#xD;
        drugs; 10. The patient has not received tumor endocrine therapy; 11. Patients should have&#xD;
        good compliance and the family members agree to cooperate in the survival follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other malignant tumors at the same time except for recovery or tumors in&#xD;
             a stable state.&#xD;
&#xD;
          2. Pregnant or breast feeding women;&#xD;
&#xD;
          3. Patients participated in other drug clinical trials within six months;&#xD;
&#xD;
          4. Patients with many factors that affect oral drugs (such as inability to swallow,&#xD;
             chronic diarrhea, intestinal obstruction, etc.);&#xD;
&#xD;
          5. Any bleeding event with a severity level of grade ≥ 3 in CTCAE 4.0 in the 4 weeks&#xD;
             before screening;&#xD;
&#xD;
          6. Patients with known central nervous system metastasis or a history of the metastasis&#xD;
             before screening;&#xD;
&#xD;
          7. Patients with hypertension who cannot be well controlled by antihypertensive drugs&#xD;
             (systolic blood pressure&gt; 140 mmHg, diastolic blood pressure&gt; 90 mmHg); those with a&#xD;
             history of unstable angina; those who are newly diagnosed with angina within 3 months&#xD;
             before screening or Myocardial infarction occurred within 6 months before screening;&#xD;
             arrhythmia requires long-term use of antiarrhythmic drugs and New York Heart&#xD;
             Association grade ≥ II cardiac insufficiency;&#xD;
&#xD;
          8. Long-term unhealed wounds or incomplete fractures;&#xD;
&#xD;
          9. A previous history of organ transplantation;&#xD;
&#xD;
         10. Imaging shows that the tumor has invaded important blood vessels or the researcher has&#xD;
             judged that the patient's tumor is highly likely to invade important blood vessels to&#xD;
             induce fatal bleeding during treatment;&#xD;
&#xD;
         11. Abnormal coagulation function (PT&gt;16s, APTT&gt;43s, TT&gt;21s, Fbg&lt;2g/L); those with&#xD;
             bleeding tendency (INR is normal without using anticoagulants in 14 days before&#xD;
             randomization); patients treated with anticoagulants or vitamin K antagonists such as&#xD;
             warfarin, heparin or their analogs; under the condition of INR ≤ 1.5, Low-dose&#xD;
             warfarin (1 mg orally, once a day) or low-dose aspirin (do not exceed 100 mg per day)&#xD;
             is permitted for preventive purposes;&#xD;
&#xD;
         12. Arteriovenous thrombosis events occurred within one year before screening, such as&#xD;
             cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis&#xD;
             (venous thrombosis caused by intravenous catheterization due to pre-chemotherapy,&#xD;
             except those who have been cured), and pulmonary embolism;&#xD;
&#xD;
         13. Those who have a history of psychotropic drug abuse and can't be prevented or have&#xD;
             mental disorders;&#xD;
&#xD;
         14. Have a history of immunodeficiency, or have a history of organ transplantation;&#xD;
&#xD;
         15. According to the judgment of the investigator, there are accompanying diseases that&#xD;
             seriously endanger the safety of the patient or affect the completion of the study;&#xD;
&#xD;
         16. Have a history of surgery within 28 days;&#xD;
&#xD;
         17. A history of abdominal fistula or gastrointestinal perforation within 28 days;&#xD;
&#xD;
         18. People who may receive other systemic anti-tumor treatments or plan to undergo ovarian&#xD;
             cancer reduction surgery during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xipeng Wang, Doctor</last_name>
    <phone>86-021-25078999</phone>
    <email>wangxipeng@xinhuamed.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xipeng Wang, Doctor</last_name>
      <phone>86-2507-8999</phone>
      <email>wangxipeng@xinhuamed.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

